FRR Shares (Makes you Realise)

Equity

Home/ Are You A Trader/ Market Info/ Company Profile/ Smart Quotes

COMPANY PROFILE

JUBILANT PHARMOVA LTD.

NSE : JUBLPHARMABSE : 530019ISIN CODE : INE700A01033Industry : Pharmaceuticals & DrugsHouse : Jubilant Bhartia

BSE1064.55-4.1 (-0.38 %)

PREV CLOSE (Rs.) 1068.65

OPEN PRICE (Rs.) 1058.65

BID PRICE (QTY) 1063.60 (23)

OFFER PRICE (QTY) 1066.00 (11)

VOLUME 5801

TODAY'S LOW / HIGH (Rs.)1043.25 1083.55

52 WK LOW / HIGH (Rs.)616.85 1309

NSE1075.756.6 (+0.62 %)

PREV CLOSE( Rs. ) 1069.15

OPEN PRICE (Rs.) 1050.00

BID PRICE (QTY) 1076.20 (1)

OFFER PRICE (QTY) 1076.55 (24)

VOLUME 251675

TODAY'S LOW / HIGH(Rs.) 1042.45 1083.00

52 WK LOW / HIGH (Rs.)617.05 1309.9

More From Company Profile

Smart Quotes

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Trade Value (Rs. in Lacs)

61.75

Dividend Yield(%)

0.47

TTM EPS (Rs.)

1.21

P/E Ratio

891.60

Book Value (Rs.)

145.54

Face Value (Rs.)

MCap (Rs. in Mn)

171187.40

Price/Earning (TTM)

236.77

Price/Sales (TTM)

23.32

Price/Book (MRQ)

7.38

PAT Margin (%)

4.03

ROCE (%)

2.64

Incorporation Year : 21-06 1978

Management Info :

Shyam S Bhartia - Chairman Priyavrat Bhartia - Managing Director

Registered Office :

Address : Bhartiagram ,Jyotiba Phoolay Nagar, ,
Gajraula,
Uttar Pradesh-244223

Phone : 05924-267437

Email : invstors@jubl.com

Website : www.jubilantpharmova.com

Registrars Details :

Alankit Assignments Ltd.

205-208 , Anarkali Complex,Jhandewala Extension,,New Delhi

Listing : BSE, NSE

NEWS

20Mar Jubilant Pharmova’s arm inks Sharehold
Jubilant Pharmova’s step down subsidiary -- Jubilant Biosys Innovative R..

13Mar Jubilant Pharmova's arm gets EIR with
Jubilant Pharmova’s subsidiary -- Jubilant Cadista Pharmaceuticals Inc.,..

13Mar Jubilant Pharmova trades higher on the
Jubilant Pharmova is currently trading at Rs. 867.05, up by 1.80 points..

Financials

	QTR Mar 25	ANNUAL 25
Net Profit	136	192
Gross Profit	235	376
Operating Profit	439	1317
Net Sales	2173	7457

Rs. in Millions

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Emcure Pharma (BSE)

1288.65 (10.00%)

M.Cap (Rs. in Cr)24417.77

Astrazeneca Pharma I (BSE)

8080.05 (0.98%)

M.Cap (Rs. in Cr)20200.13

RPG Life Sciences (BSE)

2223.45 (2.50%)

M.Cap (Rs. in Cr)3677.37

Sanofi India (BSE)

6309.60 (0.80%)

M.Cap (Rs. in Cr)14542.69

Shareholding Pattern

	PROMOTERS	50.68%
	NON-INSTITUTION	25.06%
	MUTUAL FUNDS/UTI	3.66%
	FI/BANKS/INSURANCE	1.36%
	GOVERNMENT	0%
	FII	0%

Mf Holding

Scheme Name

Hold(%)

Kotak Healthcare Fu...

3.05

Kotak Consumption F...

2.15

Kotak Special Oppor...

2.09

Kotak MNC Fund-Reg(G)

1.55

HDFC Pharma and Hea...

1.31

Bandhan Innovation ...

1.08

Quant Small Cap Fund(G)

1.06

Attention Investors

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month, Issued in the interest of Investors.

Risk Disclosure on Derivatives | Smart ODR | Mandatory Display | KYC Validation Links

BSE / NSE SEBI Registration No. INZ000279232, Depository Participant SEBI Registration No. – IN DP CDSL 132-2015

Mutual funds - ARN No. 81648 , Investment Adviser SEBI Registration No. : INA000008668.

close X

Download Client Registration Documents

Download Client Registration Documents (Rights & Obligations, Risk Disclosure Document, Do's & Don't's) in Vernacular Language :

Assamese Bengali Gujarati Hindi Kanada

Kashmiri Konkani Malyalam Marathi Oriya

Punjabi Sindhi Tamil Telegu Urdu

NOTE : " This document is a translated version of the client registration documents in English and is being provided in vernacular language to facilitate better understanding by the investors. In case of any ambiguity, the contents of the English version would prevail. "

CLOSE X

Risk Disclosures On Derivatives

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22